NAD(P)H Dehydrogenase (Quinone)
"NAD(P)H Dehydrogenase (Quinone)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A flavoprotein that reversibly catalyzes the oxidation of NADH or NADPH by various quinones and oxidation-reduction dyes. The enzyme is inhibited by dicoumarol, capsaicin, and caffeine.
Descriptor ID |
D016660
|
MeSH Number(s) |
D08.811.682.608.800.500
|
Concept/Terms |
NAD(P)H Dehydrogenase (Quinone)- NAD(P)H Dehydrogenase (Quinone)
- Quinone Reductase
- Reductase, Quinone
- Phylloquinone Reductase
- Reductase, Phylloquinone
- DT Diaphorase
- Diaphorase, DT
- Menadione Reductase
- Reductase, Menadione
|
Below are MeSH descriptors whose meaning is more general than "NAD(P)H Dehydrogenase (Quinone)".
Below are MeSH descriptors whose meaning is more specific than "NAD(P)H Dehydrogenase (Quinone)".
This graph shows the total number of publications written about "NAD(P)H Dehydrogenase (Quinone)" by people in this website by year, and whether "NAD(P)H Dehydrogenase (Quinone)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1997 | 1 | 0 | 1 |
1999 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 1 | 1 | 2 |
2012 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2018 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "NAD(P)H Dehydrogenase (Quinone)" by people in Profiles.
-
Ofosu-Boateng M, Shaik F, Choi S, Ekuban FA, Gebreyesus LH, Twum E, Nnamani DO, Yeyeodu ST, Yadak N, Collier DM, Gyamfi MA. High-fat diet induced obesity promotes inflammation, oxidative stress, and hepatotoxicity in female FVB/N mice. Biofactors. 2024 May-Jun; 50(3):572-591.
-
El Rouby N, Rodrigues Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, Caleb Junior de Lima Santos P, Duconge J, Cavallari LH. Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clin Transl Sci. 2021 01; 14(1):268-276.
-
Zhang M, Park EJ, Kondratyuk TP, Pezzuto JM, Sun D. Synthesis and Structure-Activity Relationships of Tetrahydro-?-carboline Derivatives as Anticancer and Cancer-chemopreventive Agents. Anticancer Res. 2018 Aug; 38(8):4425-4433.
-
Youn UJ, Park EJ, Kondratyuk TP, Sang-Ngern M, Wall MM, Wei Y, Pezzuto JM, Chang LC. Anti-inflammatory and Quinone Reductase Inducing Compounds from Fermented Noni (Morinda citrifolia) Juice Exudates. J Nat Prod. 2016 06 24; 79(6):1508-13.
-
Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics. 2012 Dec; 13(16):1925-35.
-
Shen L, Park EJ, Kondratyuk TP, Guendisch D, Marler L, Pezzuto JM, Wright AD, Sun D. Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents. Bioorg Med Chem. 2011 Nov 01; 19(21):6182-95.
-
Lin X, Yang H, Zhou L, Guo Z. Nrf2-dependent induction of NQO1 in mouse aortic endothelial cells overexpressing catalase. Free Radic Biol Med. 2011 Jul 01; 51(1):97-106.
-
Ping Z, Liu W, Kang Z, Cai J, Wang Q, Cheng N, Wang S, Wang S, Zhang JH, Sun X. Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme. Brain Res. 2010 Jul 09; 1343:178-85.
-
Pickett G, Seagrave J, Boggs S, Polzin G, Richter P, Tesfaigzi Y. Effects of 10 cigarette smoke condensates on primary human airway epithelial cells by comparative gene and cytokine expression studies. Toxicol Sci. 2010 Mar; 114(1):79-89.
-
Onyenwoke RU, Wiegel J. Iron (III) reduction: A novel activity of the human NAD(P)H:oxidoreductase. Biochem Biophys Res Commun. 2007 Feb 09; 353(2):389-93.